Is remdesivir important in clinical practice as a treatment of COVID-19? A study based on meta-analysis data.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Vitamin D supplementation to treat SARS-CoV-2 positive patients. Evidence from meta-analysis.Cardiology journal · 2022
   Pooled it
2. A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19.Cardiology journal · 2021
   Pooled it
3. Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency.Journal of clinical epidemiology · 2022
   Article
4. Remdesivir shifts circadian rhythmicity to eveningness; similar to the most prevalent chronotype in ADHD.Journal of neural transmission (Vienna, Austria : 1996) · 2021
   Article

Corrections and comments

• Comment on
  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.2020

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as